Form 4: CEO Exercises Options, Boosts Nuo Therapeutics Stake

Nuo Therapeutics CEO and CFO David Jorden exercised options for 125,000 shares, increasing his direct beneficial ownership.

Summary

• David Emerson Jorden, who serves as CEO, CFO, and Director of Nuo Therapeutics, Inc. (AURX), reported a change in his beneficial ownership.
• On January 1, 2026, Jorden exercised an option to purchase 125,000 shares of common stock at an exercise price of $0.4 per share.
• As part of a net exercise, 25,381 shares were withheld by the issuer to cover the exercise price, based on a closing price of $1.97 per share.
• Jorden received a net of 99,619 shares of common stock from this transaction.
• Following these transactions, Jorden's direct beneficial ownership of common stock stands at 2,046,374 shares.

Sentiment

Score: 7

Explanation: The CEO/CFO exercised options and increased his direct beneficial ownership, which is generally viewed positively as it aligns management's interests with shareholders. The net exercise is a common practice for managing the tax implications of option exercises.

Positives

• CEO/CFO David Jorden increased his direct beneficial ownership by 99,619 shares through the exercise of stock options, aligning his interests further with shareholders.
• The exercise price of $0.4 per share is significantly lower than the $1.97 per share closing price used for withholding, indicating a substantial in-the-money value for the options.

Negatives

• 25,381 shares were disposed of (withheld) by the issuer to cover the exercise price, which slightly reduced the total number of shares acquired compared to a full cash exercise.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased alignment of the CEO/CFO's interests with shareholders due to increased direct ownership, potentially signaling confidence in the company's future.

Key Dates

Recommendation

The CEO/CFO's exercise of stock options and subsequent increase in direct beneficial ownership is a positive signal, indicating management's confidence and alignment with shareholder interests. However, this single transaction, while favorable, does not fundamentally alter the company's financial position or strategic outlook to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for existing investors, suggesting continued monitoring of the company's performance.

Keywords

Nuo Therapeutics, AURX, SEC Form 4, Insider Transaction, Stock Options, CEO, CFO, Director, Beneficial Ownership, Equity Compensation